Upon agonist binding, the bilobate ligand-binding domains of the ionot
ropic glutamate
recepto
rs(iGluR) unde
rgo a cleft closu
re whose magnitude co
rrelates b
roadly with the efficacy of the agonist.AMPA (
rs/alpha.gif" BORDER=0>-amino-5-methyl-3-hyd
roxy-4-isoxazolep
ropionic acid) and kainate a
re nonphysiological agoniststhat distinguish between subsets of iGluR. Kainate acts with low efficacy at AMPA
recepto
rs. He
re we
repo
rt that the st
ructu
re-based mutation L651V conve
rts the GluR4 AMPA
recepto
r into a dual-specificityAMPA/kainate
recepto
r fully activated by both agonists. To p
robe the ste
reochemical basis of pa
rtialagonism, we have also investigated the co
rrelation between agonist efficacy and a se
ries of vib
rationaland fluo
rescence spect
roscopic signals of agonist binding to the co
rresponding wild-type and mutant GluR4ligand-binding domains. Two signals t
rack the extent of channel activation: the maximal change in int
rinsict
ryptophan fluo
rescence and the envi
ronment of the single non-disulfide bonded C426, which appea
rs top
robe the st
rength of inte
ractions with the ligand
rs/alpha.gif" BORDER=0>-amino g
roup. Both of these signals a
rise f
rom functionalg
roups that a
re poised to detect changes in the extent of channel cleft closu
re and thus p
rovide additionalinfo
rmation about the coupling between confo
rmational changes in the ligand-binding domain and activationof the intact
recepto
r.